Physician profile
Paige Workman
NPI 1669910758
$4,274.38
in general payments reported to CMS, 2019-2025
21 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $659 · 2023: $686 · 2024: $1,452 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.94 |
| Education | $209.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.51 | 2022-2025 | |
| Janssen Biotech, INC. | $804.16 | 2023-2025 | Tremfya |
| Incyte Corporation | $303.55 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $300.83 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $294.03 | 2022-2025 | |
| Lilly USA, LLC | $268.92 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Organon LLC | $185.85 | 2024-2025 | Hadlima |
| Genzyme Corporation | $172.23 | 2024-2025 | |
| Ucb, INC. | $164.82 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $137.58 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $135.42 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $134.75 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $129.45 | 2022-2023 | Otezla |
| Pfizer INC. | $92.60 | 2022-2024 | |
| Galderma Laboratories, L.P. | $62.82 | 2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.77 | 2023-2024 | Spevigo |
| Genentech USA, INC. | $26.97 | 2023 | Xolair |
| Organogenesis INC. | $22.78 | 2025 | Affinity |
| Verrica Pharmaceuticals INC. | $21.61 | 2023 | Ycanth |
| Biofrontera INC. | $17.78 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.95 | 2025 | Cabtreo, Jublia, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.